Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)Simona Di Giambenedetto, Antonella Castagna, Giancarlo Orofino et al.|Journal of Antimicrobial Chemotherapy|2016Cited by 75
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli et al.|Journal of Antimicrobial Chemotherapy|2018Cited by 33
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)Massimiliano Fabbiani, Simona Di Giambenedetto, Annalisa Mondi et al.|Scandinavian Journal of Infectious Diseases|2013Cited by 29
Simplification to atazanavir/ritonavir plus lamivudine versus maintaining atazanavir/ritonavir+2NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trialRoberta Gagliardini, Andrea De Luca, Massimiliano Fabbiani et al.|Unknown|2016Cited by 11